Lavie, DavidTimmerman, JohnSanz, Ramon GarciaKim, Won SeogKim, Tae MinAvigdor, AbrahamDierickx, DaanJagadeesh, DeepaHerrera, Alex Francisco2024-01-252024-01-252023Lavie, D., Timmerman, J., Sanz, R. G., Kim, W.S., Kim, T. M., Avigdor, A. ... Herrera, A. F. (2023). KEYFORM-008: Coformulated favezelimab and pembrolizumab (MK4280A) versus chemotherapy in relapsed/refractory classical Hodgkin lymphoma. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). Chicago, IL, 02-06 June, 2023.0732-183X1527-7755https://hdl.handle.net/20.500.12511/12203[Abstract Not Available]eninfo:eu-repo/semantics/closedAccessHodgkin LymphomaRefractoryChemotherapyConference Object4116Q1001053772005450